Frank Szoka

Dr. Frank Szoka is a Professor of Bioengineering, Therapeutic Science & Pharmaceutical Chemistry at the University of California School of Pharmacy in San Francisco. The principle focus of his research group is to exploit chemical, biophysical and physiological principles to devise vaccine, drug and nucleic acid delivery systems. In addition to his University commitments, Dr. Szoka is a founder of Sequus Pharmaceuticals, Inc. owned by Johnson & Johnson, GeneMedicine, inc. and ZoneOne Pharma, Inc. Sequus introduced the sterically stabilized liposome (Doxil™, Caelyx™) for anti-cancer drug delivery. ZoneOne Pharma, Inc. is developing liposome therapies to treat iron overload that occurs as a sequelae to sickle cell anemia and thalassemia.